The report provides a detailed analysis of the current acute respiratory distress syndrome (ARDS) marketed drugs and late-stage pipeline drugs. Inside the ARDS Market | How Tech, Awareness, Rising ...

Emerging Acute Respiratory Distress Syndrome therapies in the different phases of clinical trials are- RSBT-001, AVM0703, CYP 001, AV 001, ALT-100, STSA-1002, GEn-1124, Descartes 30, Rhu-pGSN ...

Surveillance and medical protocols are in place, but environmental factors for the epidemic reappearing regularly cannot be ruled out.

Nationally Recognized Texas Children’s Hospital Adds First-In-Class Therapy as a Potential Life-Saving Treatment in ...

Three De-suup trainees, a man and two women, have died at the national referral hospital after a Leptospirosis outbreak at a ...

How fast does a fish disappear? How long does it take to erase all evidence of its life, to turn it into a fillet? What about ...

In the U.S. alone, ARDS affects over 500,000 patients per year, or roughly 10% of all ICU admissions. With no effective pharmacological therapies currently available for ARDS and its high ...

Over the last 7 days, the United States market has risen by 1.7%, and over the past year, it is up 12%, with earnings forecasted to grow by 15% annually. For investors seeking opportunities beyond ...

The R/I ratio showed limited accuracy in predicting lung recruitability in ARDS but reliably identified low recruiters.

Recent double-blind, randomized, controlled trials reported that human umbilical cord-derived mesenchymal stem cell (MSC) infusions in COVID-19 patients with acute respiratory distress syndrome ...

Therefore, the Health Ministry encourages the BPH to enforce stricter regulations for upcoming Hajj seasons. "With synergy and commitment from all parties, the Health Ministry hopes to reduce the ...